NCT07753356
VALIDATION OF FUSION CEMEP SCORE FOR OMITTING SYSTEMATIC PROSTATE BIOPSY
Not Yet Recruiting · Not specified · Marcelo Ruben Oliva · registry updated 2026-08-07
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This study aims to prospectively validate the Fusion CEMEP score to assess the safety and efficacy of omitting systematic prostate biopsy in patients undergoing multiparametric magnetic resonance imaging-targeted biopsy. The main objective is to determine if target-only biopsy guided by the score is sufficient for clinically significant prostate cancer detection while reducing overtreatment and unnecessary cores.
Inclusion
- Adult male patients with clinical suspicion of prostate cancer.
- Patients scheduled to undergo multiparametric MRI-targeted prostate biopsy.
- Signed informed consent.
Exclusion
- Prior treatment for prostate cancer.
- Contraindications to prostate biopsy or multiparametric MRI.